The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology discussed some of the key research needs for migraine care going forward. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
"Hopefully, some of the newer intranasal delivery medications that are coming out will have trials looking at the acute cluster [headache]. That’s something we’re hoping to see come to fruition."
After more than 2 years of mostly virtual settings, clinicians from across the globe gathered in-person for the 2022 American Academy of Neurology (AAN) Annual Meeting, held April 2-7, in Seattle, Washington. Among the attendees were Rashmi B. Halker Singh, MD, FAAN, and Paul G. Mathew, MD, DNBPAS, FAAN, FAHS, the respective chair and vice-chair of the Headache and Facial Pain Section of the AAN.
For years, the duo have been leaders within the migraine field, both in research and in their clinical practice. Halker-Singh, a neurologist at Mayo Clinic in Arizona, is also the department education coordinator for headache neurology and a member of the department of neurology’s Headache Medicine Search Committee. Outside of her practice, she remains a chair of the Women’s Leadership Subcommittee and ally of the DEI Taskforce Committee at the American Headache Society (AHS). In addition to his obligations with the AAN, Mathew is currently an assistant professor of neurology at Harvard Medical School (HMS) and an affiliate member of the HMS Division of Sleep Medicine. He is the current chairman of the AHS Procedural Special Interest Section, a member of the board of directors of the National Headache Foundation, and an executive board member of the Indian Medical Association of New England.
At AAN 2022, both experts sat down with NeurologyLive® to discuss some of the most pertinent topics related to headache and migraine medicine. In this interview, they provided commentary on some of the top focuses within the field, including the need to improve diagnosis rates, therapies for cluster headache, and attracting the next generation of headache specialists.